NGM Biopharmaceuticals, Inc. is committed to pursuing unexplored biological mechanisms in order to develop breakthrough biotherapeutics with the potential to redefine medical treatment practices and enhance outcomes. Relying on human clinical and genetic observations, the Company has established a unique discovery platform to identify and validate novel targets that impact the underlying etiology of metabolic diseases.

NGM's strategy is to elucidate the roles of these hormones and receptors in the systemic regulation of cardiometabolic diseases. With this holistic approach, NGM is generating a pipeline of innovative protein, peptide and antibody drug candidates as novel treatments for diseases such as diabetes, obesity, dyslipidemias, bile acid-related disorders and cardiovascular diseases.